Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

MLA

Boudewijns, Steve, et al. “Adjuvant Dendritic Cell Vaccination Induces Tumor-Specific Immune Responses in the Majority of Stage III Melanoma Patients.” OncoImmunology, vol. 5, no. 7, July 2016, p. 1. EBSCOhost, https://doi.org/10.1080/2162402X.2016.1191732.

APA

Boudewijns, S., Bol, K. F., Schreibelt, G., Westdorp, H., Textor, J. C., van Rossum, M. M., Scharenborg, N. M., de Boer, A. J., van de Rakt, M. W. M. M., Pots, J. M., van Oorschot, T. G. M., Duiveman-de Boer, T., Olde Nordkamp, M. A., van Meeteren, W. S. E. C., van der Graaf, W. T. A., Bonenkamp, J. J., de Wilt, J. H. W., Aarntzen, E. H. J. G., Punt, C. J. A., & Gerritsen, W. R. (2016). Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. OncoImmunology, 5(7), 1. https://doi.org/10.1080/2162402X.2016.1191732

Chicago

Boudewijns, Steve, Kalijn F. Bol, Gerty Schreibelt, Harm Westdorp, Johannes C. Textor, Michelle M. van Rossum, Nicole M. Scharenborg, et al. 2016. “Adjuvant Dendritic Cell Vaccination Induces Tumor-Specific Immune Responses in the Majority of Stage III Melanoma Patients.” OncoImmunology 5 (7): 1. doi:10.1080/2162402X.2016.1191732.